Logo

Dominari Holdings Inc.

DOMH

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and a… read more

Healthcare

Biotechnology

43 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$6.07

Price

-2.73%

-$0.17

Market Cap

$93.005m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$52.812m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$19.020m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$301,506.03

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$88.600m

$109.338m

Assets

$20.738m

Liabilities

$2.860m

Debt
Debt to Assets

2.6%

-

Debt to EBITDA
Free Cash Flow

-$7.051m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases